Medical Science

Scientists Revive a Failing Antibiotic That Superbugs Had Defeated

Instead of designing a brand-new drug, researchers paired vancomycin with a small molecule that strips resistant bacteria of a key defense — restoring the antibiotic's power against one of the most dangerous hospital superbugs.

• The team used a molecule called pghi-4, discovered in 2020, to block the bacterial enzyme SagA (secreted antigen A), which drug-resistant E. faecium relies on to survive vancomycin treatment.
• The combination restored vancomycin's ability to kill resistant E. faecium in laboratory tests, opening a path to revive other failing antibiotics using similar chemical helpers.
• The discovery came from a chemistry technique called diversity oriented clicking (DOC), which rapidly builds libraries of candidate molecules — over 150 compounds were created and screened for this study.

Antibiotic resistance is one of the most urgent threats in modern medicine. Bacteria evolve constantly, and the drugs that once stopped them reliably are losing ground. Common infections are becoming harder to treat, and routine procedures — surgery, cancer therapy, organ transplants — carry greater risk when powerful antibiotics no longer work.

One of the most alarming casualties has been vancomycin, a last-resort antibiotic used against severe infections caused by MRSA, C. diff, and other hospital-acquired pathogens. Some strains of Enterococcus faecium, a notorious superbug, have learned to resist vancomycin by deploying an enzyme called secreted antigen A (SagA). This enzyme helps the bacteria fortify their cell walls and survive the antibiotic's attack.

Rather than inventing an entirely new drug — a process that can take a decade or more — researchers at Cold Spring Harbor Laboratory (CSHL) and Scripps Research took a different approach. They asked whether a companion molecule could strip the bacteria of their resistance and make vancomycin effective again.

The answer came in the form of pghi-4, a small molecule first discovered in the CSHL laboratory of Professor John Moses in 2020. When pghi-4 was combined with vancomycin and given to drug-resistant E. faecium, it blocked the SagA enzyme, collapsing the bacteria's defenses. The antibiotic moved in and killed the superbug.

What makes this approach powerful is that pghi-4 itself is not an antibiotic — it does not kill bacteria directly. It is an adjuvant, a chemical helper whose sole job is to disable resistance machinery. The same strategy could be applied to other antibiotics that bacteria have learned to evade, potentially rescuing a whole class of drugs that were on the verge of obsolescence.

The molecules used in the study came from a library built through a technique called diversity oriented clicking (DOC), developed in the Moses laboratory. DOC allows chemists to rapidly assemble diverse molecular structures, creating libraries of candidate compounds far faster than traditional methods. The library now contains more than 150 compounds, and several have already contributed to research on both antibiotic resistance and cancer.

For Moses, the finding is a reminder that major medical breakthroughs can come from basic chemistry. "This discovery came from fundamental chemical research," he said. "Reaction development led to the discovery of the first inhibitor of an important enzyme involved in antibiotic resistance."

The study was funded by the National Institutes of Health, the National Cancer Institute, and other agencies. The researchers hope that similar adjuvant-based strategies may eventually be developed for other drug-resistant infections, including resistant tuberculosis.